Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

Open Access 01-02-2018 | Basic Science

Plasma levels of hypoxia-regulated factors in patients with age-related macular degeneration

Authors: Zygoula Ioanna, Schori Christian, Grimm Christian, Barthelmes Daniel

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 2/2018

Abstract

Purpose

Various hypoxia-related proteins are differentially expressed in the retina and secreted to the vitreous and/or aqueous humor of patients affected by dry or neovascular age-related macular degeneration (nAMD). To determine whether these conditions alter concentrations of cytokines also in the systemic circulation, we measured plasma levels of six hypoxia-related proteins.

Methods

Plasma was prepared from EDTA blood that was collected from patients affected by dry AMD (n = 5), nAMD (n = 11), proliferative diabetic retinopathy (PDR; n = 9), and patients with an epiretinal membrane (ERM; n = 11). ERM samples served as negative controls, PDR samples as positive controls. Protein concentrations of vascular endothelial growth factor (VEGF), erythropoietin (EPO), angiopoietin-like 4 (ANGPTL4), placental growth factor (PlGF), tumor necrosis factor alpha (TNF-α), and pigment epithelium-derived factor (PEDF) were determined by enzyme-linked immunosorbent assay (ELISA).

Results

The concentration of PlGF was significantly increased in plasma of patients affected by nAMD. Although no statistically significant differences were found for EPO, ANGPTL4, PlGF, TNF-α, and PEDF, the mean concentration of VEGF was lowest in the nAMD group. Plasma concentrations of the six factors did not correlate with gender or age of patients.

Conclusions

nAMD may increase plasma concentrations of PlGF, making it a candidate as a biomarker for the neovascular form of AMD. Other factors, however, were not differentially regulated, suggesting that their systemic concentrations are not generally increased in hypoxia-related retinal diseases.

Klein R, Klein BE, Linton KL (1992) Prevalence of age-related maculopathy. Beaver Dam Eye Study Ophthalmol 99:933–943

Mitchell P, Smith W, Attebo K, Wang JJ (1995) Prevalence of age-related maculopathy in Australia. Blue Mountains Eye Study Ophthalmol 102:1450–1460

Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF, de Jong PT (1995) The prevalence of age-related maculopathy in the Rotterdam study. Ophthalmology 102:205–210CrossRefPubMed

Group MPS (1990) Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Macular photocoagulation study group. Arch Ophthalmol 108:816–824CrossRef

(1993) Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 111: 1200-1209

Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444. https://doi.org/10.1056/NEJMoa062655 CrossRefPubMed

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431. https://doi.org/10.1056/NEJMoa054481 CrossRefPubMed

Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP, Hantsbarger G, Shams N (2006) Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 113(633):e631–e634. https://doi.org/10.1016/j.ophtha.2005.10.052

Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897–1908. https://doi.org/10.1056/NEJMoa1102673 CrossRefPubMed

10.

Khan JC, Thurlby DA, Shahid H, Clayton DG, Yates JR, Bradley M, Moore AT, Bird AC (2006) Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol 90:75–80. https://doi.org/10.1136/bjo.2005.073643 CrossRefPubMedPubMedCentral

11.

Seddon JM, Cote J, Davis N, Rosner B (2003) Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol 121:785–792. https://doi.org/10.1001/archopht.121.6.785 CrossRefPubMed

12.

Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, Spencer KL, Kwan SY, Noureddine M, Gilbert JR, Schnetz-Boutaud N, Agarwal A, Postel EA, Pericak-Vance MA (2005) Complement factor H variant increases the risk of age-related macular degeneration. Science 308:419–421. https://doi.org/10.1126/science.1110359 CrossRefPubMed

13.

Cao S, Ko A, Partanen M, Pakzad-Vaezi K, Merkur AB, Albiani DA, Kirker AW, Wang A, Cui JZ, Forooghian F, Matsubara JA (2013) Relationship between systemic cytokines and complement factor H Y402H polymorphism in patients with dry age-related macular degeneration. Am J Ophthalmol 156:1176–1183. https://doi.org/10.1016/j.ajo.2013.08.003 CrossRefPubMedPubMedCentral

14.

DaCosta J (2013) Minocycline protects retinal pigment epithelial cells from hypoxia. ARVO Meeting Abstr 54:4108

15.

McLeod DS, Grebe R, Bhutto I, Merges C, Baba T, Lutty GA (2009) Relationship between RPE and Choriocapillaris in age-related macular degeneration. Invest Ophthalmol Vis Sci 50:4982–4991. https://doi.org/10.1167/Iovs.09-3639 CrossRefPubMedPubMedCentral

16.

Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92:5510–5514CrossRefPubMedPubMedCentral

17.

Wang GL, Semenza GL (1993) General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A 90:4304–4308CrossRefPubMedPubMedCentral

18.

Vadlapatla RK, Vadlapudi AD, Pal D, Mukherji M, Mitra A (2013) Ritonavir inhibits HIF-1{alpha} mediated VEGF expression in retinal pigment epithelial cells. ARVO Meeting Abstr 54:3275

19.

Ozaki H, Yu AY, Della N, Ozaki K, Luna JD, Yamada H, Hackett SF, Okamoto N, Zack DJ, Semenza GL, Campochiaro PA (1999) Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci 40:182–189PubMed

20.

Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT (1997) Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 81:154–162CrossRefPubMedPubMedCentral

21.

Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR (1996) Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 37:855–868PubMed

22.

Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, Lam DS (2006) Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 141:456–462. https://doi.org/10.1016/j.ajo.2005.10.012 CrossRefPubMed

23.

Wang F, Rendahl KG, Manning WC, Quiroz D, Coyne M, Miller SS (2003) AAV-mediated expression of vascular endothelial growth factor induces choroidal neovascularization in rat. Invest Ophthalmol Vis Sci 44:781–790CrossRefPubMed

24.

Babapoor-Farrokhran S, Jee K, Puchner B, Hassan SJ, Xin X, Rodrigues M, Kashiwabuchi F, Ma T, Hu K, Deshpande M, Daoud Y, Solomon S, Wenick A, Lutty GA, Semenza GL, Montaner S, Sodhi A (2015) Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy. Proc Natl Acad Sci U S A 112:E3030–E3039. https://doi.org/10.1073/pnas.1423765112 CrossRefPubMedPubMedCentral

25.

Rakic JM, Lambert V, Devy L, Luttun A, Carmeliet P, Claes C, Nguyen L, Foidart JM, Noel A, Munaut C (2003) Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 44:3186–3193CrossRefPubMed

26.

He X, Cheng R, Benyajati S, Ma JX (2015) PEDF and its roles in physiological and pathological conditions: implication in diabetic and hypoxia-induced angiogenic diseases. Clin Sci (Lond) 128:805–823. https://doi.org/10.1042/CS20130463 CrossRef

27.

Li S, Fu XA, Zhou XF, Chen YY, Chen WQ (2012) Angiogenesis-related cytokines in serum of proliferative diabetic retinopathy patients before and after vitrectomy. Int J Ophthalmol 5:726–730. https://doi.org/10.3980/j.issn.2222-3959.2012.06.14 PubMedPubMedCentral

28.

Zhou J, Wang S, Xia X (2012) Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Curr Eye Res 37:416–420. https://doi.org/10.3109/02713683.2012.661114 CrossRefPubMed

29.

Mirshahi A, Hoehn R, Lorenz K, Kramann C, Baatz H (2012) Anti-tumor necrosis factor alpha for retinal diseases: current knowledge and future concepts. J Ophthalmic Vis Res 7:39–44PubMedPubMedCentral

30.

Lim JI, Spee C, Hinton DR (2010) A comparison of hypoxia-inducible factor-alpha in surgically excised neovascular membranes of patients with diabetes compared with idiopathic epiretinal membranes in nondiabetic patients. Retina 30:1472–1478. https://doi.org/10.1097/IAE.0b013e3181d6df09 CrossRefPubMedPubMedCentral

31.

Stitt AW, Gardiner TA, Archer DB (1995) Histological and ultrastructural investigation of retinal microaneurysm development in diabetic patients. Br J Ophthalmol 79:362–367CrossRefPubMedPubMedCentral

32.

Boeri D, Maiello M, Lorenzi M (2001) Increased prevalence of microthromboses in retinal capillaries of diabetic individuals. Diabetes 50:1432–1439CrossRefPubMed

33.

Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP (2001) Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 158:147–152. https://doi.org/10.1016/S0002-9440(10)63952-1 CrossRefPubMedPubMedCentral

34.

Jiang F, Tang YT, Guo L, Jiao XY (2013) The role of insulin-like growth factor I and hypoxia inducible factor 1alpha in vascular endothelial growth factor expression in type 2 diabetes. Ann Clin Lab Sci 43:37–44PubMed

35.

Wang X, Wang G, Wang Y (2009) Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy. Am J Ophthalmol 148:883–889. https://doi.org/10.1016/j.ajo.2009.07.007 CrossRefPubMed

36.

Zehetner C, Kirchmair R, Kralinger M, Kieselbach G (2013) Correlation of vascular endothelial growth factor plasma levels and glycemic control in patients with diabetic retinopathy. Acta Ophthalmol 91:e470–e473. https://doi.org/10.1111/aos.12081 CrossRefPubMed

37.

Lip PL, Chatterjee S, Caine GJ, Hope-Ross M, Gibson J, Blann AD, Lip GY (2004) Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade. Br J Ophthalmol 88:1543–1546. https://doi.org/10.1136/bjo.2004.048587 CrossRefPubMedPubMedCentral

38.

Gholamhossein Y, Behrouz H, Asghar Z (2014) Diabetic retinopathy risk factors: plasma erythropoietin as a risk factor for proliferative diabetic retinopathy. Korean J Ophthalmol 28:373–378. https://doi.org/10.3341/kjo.2014.28.5.373 CrossRefPubMedPubMedCentral

39.

Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285:245–248CrossRefPubMed

40.

Larsson A, Skoldenberg E, Ericson H (2002) Serum and plasma levels of FGF-2 and VEGF in healthy blood donors. Angiogenesis 5:107–110CrossRefPubMed

41.

Wognum AW, Lam V, Goudsmit R, Krystal G (1990) A specific in vitro bioassay for measuring erythropoietin levels in human serum and plasma. Blood 76:1323–1329PubMed

42.

Bruno CM, Neri S, Sciacca C, Bertino G, Di Prima P, Cilio D, Pellicano R, Caruso L, Cristaldi R (2004) Plasma erythropoietin levels in anaemic and non-anaemic patients with chronic liver diseases. World J Gastroenterol 10:1353–1356CrossRefPubMedPubMedCentral

43.

Jonker JT, Smit JW, Hammer S, Snel M, van der Meer RW, Lamb HJ, Mattijssen F, Mudde K, Jazet IM, Dekkers OM, de Roos A, Romijn JA, Kersten S, Rensen PC (2013) Dietary modulation of plasma angiopoietin-like protein 4 concentrations in healthy volunteers and in patients with type 2 diabetes. Am J Clin Nutr 97:255–260. https://doi.org/10.3945/ajcn.112.043687 CrossRefPubMed

44.

Jeevaratnam K, Nadarajah VD, Judson JP, Nalliah S, Abdullah MF (2010) Periodic assessment of plasma sFlt-1 and PlGF concentrations and its association with placental morphometry in gestational hypertension (GH) - a prospective follow-up study. BMC Pregnancy Childbirth 10:58. https://doi.org/10.1186/1471-2393-10-58 CrossRefPubMedPubMedCentral

45.

Krauss T, Pauer HU, Augustin HG (2004) Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 23:101–111. https://doi.org/10.1081/PRG-120028286 CrossRefPubMed

46.

Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S, Gedrich K, Pollmacher T (2006) TNF-alpha, soluble TNF receptor and interleukin-6 plasma levels in the general population. Eur Cytokine Netw 17:196–201PubMed

47.

Petersen SV, Valnickova Z, Enghild JJ (2003) Pigment-epithelium-derived factor (PEDF) occurs at a physiologically relevant concentration in human blood: purification and characterization. Biochem J 374:199–206. https://doi.org/10.1042/BJ20030313 CrossRefPubMedPubMedCentral

48.

Li X, Wang T, Yang T, Shen Y, An J, Liu L, Dong J, Guo L, Li D, Zhang X, Chen L, Xu D, Wen F (2015) Elevated plasma levels of pigment epithelium-derived factor correlated with inflammation and lung function in COPD patients. Int J Chron Obstruct Pulmon Dis 10:587–594. https://doi.org/10.2147/COPD.S78546 PubMedPubMedCentral

49.

Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO (2003) Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 22:1–29CrossRefPubMed

50.

Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, Suzuma I, Ohashi H, Ojima T, Murakami T, Kobayashi T, Masuda S, Nagao M, Yoshimura N, Takagi H (2005) Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 353:782–792. https://doi.org/10.1056/NEJMoa041773 CrossRefPubMed

51.

Yao YG, Yang HS, Cao Z, Danielsson J, Duh EJ (2005) Upregulation of placental growth factor by vascular endothelial growth factor via a post-transcriptional mechanism. FEBS Lett 579:1227–1234. https://doi.org/10.1016/j.febslet.2005.01.017 CrossRefPubMed

52.

Zheng L, Gong B, Hatala DA, Kern TS (2007) Retinal ischemia and reperfusion causes capillary degeneration: similarities to diabetes. Invest Ophthalmol Vis Sci 48:361–367. https://doi.org/10.1167/iovs.06-0510 CrossRefPubMed

53.

Zhang SX, Wang JJ, Gao G, Parke K, Ma JX (2006) Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol 37:1–12. https://doi.org/10.1677/jme.1.02008 CrossRefPubMed

54.

Gao G, Li Y, Zhang D, Gee S, Crosson C, Ma J (2001) Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett 489:270–276CrossRefPubMed

55.

Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M (2002) Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol 134:348–353CrossRefPubMed

56.

Khurana R, Moons L, Shafi S, Luttun A, Collen D, Martin JF, Carmeliet P, Zachary IC (2005) Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation 111:2828–2836. https://doi.org/10.1161/CIRCULATIONAHA.104.495887 CrossRefPubMed

57.

Carnevale D, Lembo G (2015) PlGF, immune system and hypertension. Oncotarget 6:18246–18247. 10.18632/oncotarget.4914 CrossRefPubMedPubMedCentral

58.

Fong SW, Few LL, See Too WC, Khoo BY, Nik Ibrahim NN, Yahaya SA, Yusof Z, Mohd Ali R, Abdul Rahman AR, Yvonne-Tee GB (2015) Systemic and coronary levels of CRP, MPO, sCD40L and PlGF in patients with coronary artery disease. BMC Res Notes 8:679. https://doi.org/10.1186/s13104-015-1677-8 CrossRefPubMedPubMedCentral

59.

Hogg RE, Woodside JV, Gilchrist SE, Graydon R, Fletcher AE, Chan W, Knox A, Cartmill B, Chakravarthy U (2008) Cardiovascular disease and hypertension are strong risk factors for choroidal neovascularization. Ophthalmology 115:1046–1052 e1042. https://doi.org/10.1016/j.ophtha.2007.07.031 CrossRefPubMed

60.

Ma Y, Zhang Y, Zhao T, Jiang YR (2012) Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab. Am J Ophthalmol 153:307–313 e302. https://doi.org/10.1016/j.ajo.2011.08.006 CrossRefPubMed

61.

Lip PL, Belgore F, Blann AD, Hope-Ross MW, Gibson JM, Lip GY (2000) Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. Invest Ophthalmol Vis Sci 41:2115–2119PubMed

62.

Wang J, Chen S, Jiang F, You C, Mao C, Yu J, Han J, Zhang Z, Yan H (2014) Vitreous and plasma VEGF levels as predictive factors in the progression of proliferative diabetic retinopathy after vitrectomy. PLoS One 9:e110531. https://doi.org/10.1371/journal.pone.0110531 CrossRefPubMedPubMedCentral

63.

Kaiser A, Vollenweider P, Waeber G, Marques-Vidal P (2012) Prevalence, awareness and treatment of type 2 diabetes mellitus in Switzerland: the CoLaus study. Diabet Med 29:190–197. https://doi.org/10.1111/j.1464-5491.2011.03422.x CrossRefPubMed

64.

Kakizawa H, Itoh M, Itoh Y, Imamura S, Ishiwata Y, Matsumoto T, Yamamoto K, Kato T, Ono Y, Nagata M, Hayakawa N, Suzuki A, Goto Y, Oda N (2004) The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients. Metabolism 53:550–555CrossRefPubMed

65.

Tsai DC, Charng MJ, Lee FL, Hsu WM, Chen SJ (2006) Different plasma levels of vascular endothelial growth factor and nitric oxide between patients with choroidal and retinal neovascularization. Ophthalmologica 220:246–251. https://doi.org/10.1159/000093079 CrossRefPubMed

66.

Mohan N, Monickaraj F, Balasubramanyam M, Rema M, Mohan V (2012) Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy. J Diabetes Complicat 26:435–441. https://doi.org/10.1016/j.jdiacomp.2012.05.005 CrossRefPubMed

67.

Ogata N, Matsuoka M, Matsuyama K, Shima C, Tajika A, Nishiyama T, Wada M, Jo N, Higuchi A, Minamino K, Matsunaga H, Takeda T, Matsumura M (2007) Plasma concentration of pigment epithelium-derived factor in patients with diabetic retinopathy. J Clin Endocrinol Metab 92:1176–1179. https://doi.org/10.1210/jc.2006-2249 CrossRefPubMed

68.

Doganay S, Evereklioglu C, Er H, Turkoz Y, Sevinc A, Mehmet N, Savli H (2002) Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye (Lond) 16:163–170. https://doi.org/10.1038/sj/EYE/6700095 CrossRef

69.

Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S (2006) Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye (Lond) 20:1366–1369. https://doi.org/10.1038/sj.eye.6702138 CrossRef

70.

Machalinska A, Safranow K, Mozolewska-Piotrowska K, Dziedziejko V, Karczewicz D (2012) PEDF and VEGF plasma level alterations in patients with dry form of age-related degeneration--a possible link to the development of the disease. Klin Ocz 114:115–120

71.

Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA (1995) Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 113:1538–1544CrossRefPubMed

72.

Grimm C, Wenzel A, Groszer M, Mayser H, Seeliger M, Samardzija M, Bauer C, Gassmann M, Reme CE (2002) HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med 8:718–724. https://doi.org/10.1038/nm723 CrossRefPubMed

73.

Xin X, Rodrigues M, Umapathi M, Kashiwabuchi F, Ma T, Babapoor-Farrokhran S, Wang S, Hu J, Bhutto I, Welsbie DS, Duh EJ, Handa JT, Eberhart CG, Lutty G, Semenza GL, Montaner S, Sodhi A (2013) Hypoxic retinal Muller cells promote vascular permeability by HIF-1-dependent up-regulation of angiopoietin-like 4. Proc Natl Acad Sci U S A 110:E3425–E3434. https://doi.org/10.1073/pnas.1217091110 CrossRefPubMedPubMedCentral

74.

Tudisco L, Della Ragione F, Tarallo V, Apicella I, D'Esposito M, Matarazzo MR, De Falco S (2014) Epigenetic control of hypoxia inducible factor-1alpha-dependent expression of placental growth factor in hypoxic conditions. Epigenetics 9:600–610. https://doi.org/10.4161/epi.27835 CrossRefPubMedPubMedCentral

75.

Hempel SL, Monick MM, Hunninghake GW (1996) Effect of hypoxia on release of IL-1 and TNF by human alveolar macrophages. Am J Respir Cell Mol Biol 14:170–176. https://doi.org/10.1165/ajrcmb.14.2.8630267 CrossRefPubMed

76.

Yang XM, Yafai Y, Wiedemann P, Kuhrt H, Wang YS, Reichenbach A, Eichler W (2012) Hypoxia-induced upregulation of pigment epithelium-derived factor by retinal glial (Muller) cells. J Neurosci Res 90:257–266. https://doi.org/10.1002/jnr.22732 CrossRefPubMed

Title: Plasma levels of hypoxia-regulated factors in patients with age-related macular degeneration
Authors: Zygoula Ioanna
Schori Christian
Grimm Christian
Barthelmes Daniel
Publication date: 01-02-2018
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 2/2018
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-017-3846-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Plasma levels of hypoxia-regulated factors in patients with age-related macular degeneration

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2018

Functional and structural outcomes of ILM peeling in uncomplicated macula-off RRD using microperimetry & en-face OCT

Association between traditional clinical high-risk features and gene expression profile classification in uveal melanoma

Mechanism of accommodation assessed by change in precisely registered ocular images associated with concurrent change in auto-refraction

Long-term changes in autosomal dominant vitreoretinochoroidopathy (ADVIRC)

Recovery of macular cone photoreceptors in Vogt-Koyanagi-Harada disease

Development of a test grid using Eye Movement Perimetry for screening glaucomatous visual field defects